Murray McCutcheon - Abcellera Biologics Senior Partnering
| ABCL Stock | USD 2.95 0.19 6.88% |
Executive
Murray McCutcheon is Senior Partnering of Abcellera Biologics
| Address | 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 |
| Phone | 604 559 9005 |
| Web | https://www.abcellera.com |
Abcellera Biologics Management Efficiency
The company has return on total asset (ROA) of (0.1326) % which means that it has lost $0.1326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1555) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.11 this year. Return On Capital Employed is expected to rise to -0.16 this year. At this time, Abcellera Biologics' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 99 M this year, although the value of Non Current Assets Total will most likely fall to about 317.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lee MD | PTC Therapeutics | 56 | |
| Ronald Plasterk | CureVac NV | N/A | |
| Diane Berry | Sarepta Therapeutics | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Brian MBA | Iovance Biotherapeutics | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Sarah Fakih | CureVac NV | N/A | |
| Meg Dodge | Krystal Biotech | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| David Chien | Krystal Biotech | N/A | |
| Stephane Paquette | Krystal Biotech | N/A | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Linda Carter | PTC Therapeutics | N/A | |
| Myriam MD | CureVac NV | 58 | |
| Kathryn Romano | Krystal Biotech | 42 | |
| Emily Hill | PTC Therapeutics | 44 | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 |
Abcellera Biologics Leadership Team
Elected by the shareholders, the Abcellera Biologics' board of directors comprises two types of representatives: Abcellera Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abcellera. The board's role is to monitor Abcellera Biologics' management team and ensure that shareholders' interests are well served. Abcellera Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abcellera Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Veronique Lecault, COO Director | ||
| Bo Barnhart, Scientific Director | ||
| Andrew MBA, Chief Officer | ||
| JD Esq, Chief Officer | ||
| Murray McCutcheon, Senior Partnering | ||
| M CIPD, Sr Culture | ||
| Ester Falconer, Chief Officer | ||
| Alexandra MSc, Ma Communications | ||
| Esq JD, CCO, Officer | ||
| Josephine Hellschlienger, Manager Relations | ||
| Adam MAICD, Senior Discovery | ||
| Tiffany BSc, VP Communications | ||
| Neil MBA, Chief Officer | ||
| Carl Hansen, President CEO | ||
| CGA CPA, Senior Accounting | ||
| Graham MSc, Director Development | ||
| Kathleen BA, Head Communications |
Abcellera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abcellera Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (14.39) % | ||||
| Current Valuation | 243.47 M | ||||
| Shares Outstanding | 295.37 M | ||||
| Shares Owned By Insiders | 27.99 % | ||||
| Shares Owned By Institutions | 38.21 % | ||||
| Number Of Shares Shorted | 16.64 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 0.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.